comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 04:11:37 - browse：79

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Indictment alleges Trump's ex

knowledge

hotspot

WSS

Surge in Apellis stock fueled by confidence in safety of its eye drug

Health AI: on the border between health care and tech

Alabama IVF ruling threatens families facing fatal genetic disease

Why palliative psychiatry is worth discussing

Patients, digital health players weigh in on FTC's data privacy plan

After Optum profits sink, UnitedHealth makes changes

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Affirmative action in medical school literally saved lives

Aspartame and sugar

Cancer drug shortages should be causing more outrage

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Guidelines to prevent youth baseball injuries need more muscle

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Continuity nursing helped my family in our darkest PICU moments

A new nitrogen execution bill also undermines medical licensing

Anesthesiologist group: stop taking Ozempic before surgery

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

hotspot

In utero gene editing: an explainer

PBM reform efforts get punted in Congress

6 phony surgeries that take placebo to the extreme

Mark Cuban is blaming the wrong people for high drug costs

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Be careful with at

knowledge

focus

hotspot

knowledge